trIL-12 based cell therapy / Outpace Bio, Lyell Immunopharma - LARVOL DELTA

Outpace Bio Announces Multiple Presentations at the 2024 American Association of Cancer Research (AACR) Annual Meeting (GlobeNewswire) - "Outpace Bio...announced that nonclinical data will be presented in three poster presentations at the upcoming 2024 American Association for Cancer Research (AACR) Meeting...The upcoming presentations highlight the Company’s progress in advancing lead pipeline program OPB-101...New data will also be presented on tumor-restricted IL-12, which is designed leveraging Outpace’s OUTSMART technology to enhance solid tumor T cell therapies and is being advanced through a collaboration between Lyell Immunopharma and Outpace...'OPB-101 is the company’s lead pipeline program and is on track for an IND submission in Q4 2024.'...A poster presentation...highlights an innovative tumor-restricted IL-12 (trIL-12) technology that delivers potent IL-12 stimulation at the tumor site while avoiding systemic exposure....trIL-12 was designed leveraging Outpace’s OUTSMART technology to rapidly auto-inactivate IL-12 after inducible secretion from engineered T cells..."

IND • Preclinical • Oncology • Solid Tumor

Outpace Bio to Present New Data on Tumor-restricted IL-12 Designed Leveraging OutSmart Technology to Enhance Solid Tumor T Cell Therapies at SITC 2023 (GlobeNewswire) - "Outpace Bio...today announced it will present the latest advancements to its OutSmart^TM platform during a poster presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held from November 1-5, 2023 in San Diego, CA....The presentation highlights an innovative tumor-restricted IL-12 (trIL-12) technology that delivers potent IL-12 stimulation at the tumor site while avoiding systemic exposure. IL-12 is an immune-stimulatory cytokine that can induce potent anti-tumor activity, but systemic delivery of IL-12 has been shown to cause severe toxicity in patients."

Clinical • Oncology • Solid Tumor